Myosotis Investments B.V. is founded in 2024. It focuses on catalyzing advancements in life sciences, in particular molecular diagnostics by investing in companies that are reshaping healthcare. The firm’s portfolio includes Atwerp, Belgium based company IDEVAX B.V., which is pioneering innovative intradermal delivery methods with its patented VAX-ID device to improve vaccine and therapeutic applications, and Welsh, Uk based company Kairos Biotech Ltd., a developer of next-generation small-molecule immunotherapies aimed at enhancing transplant success and accessibility.

Myosotis Investments is committed to supporting transformative technologies that address complex medical needs and drive long-term healthcare progress.